• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR Income Opportunities Fund Appoints Eric Mogelof as Trustee, Chair and President

    12/7/20 5:00:00 PM ET
    $KIO
    $KKR
    Investment Managers
    Finance
    Investment Managers
    Finance
    Get the next $KIO alert in real time by email

    NEW YORK--(BUSINESS WIRE)--KKR Income Opportunities Fund (“KIO” or the “Fund”) (NYSE: KIO) today announced that The Board of Trustees of KIO has appointed Eric Mogelof as Trustee, Chair and President of the Fund. Mr. Mogelof replaces Suzanne Donohoe who has resigned from her role as Trustee, Chair and President of KIO. Mr. Mogelof recently joined KKR as a Partner and Global Head of KKR’s Client and Partner Group, succeeding Ms. Donohoe who was promoted to a new role as KKR’s first Global Head of Strategic Growth.

    Prior to joining KKR, Mr. Mogelof most recently served as head of PIMCO’s U.S. Global Wealth Management business and was a member of PIMCO’s Executive Committee. He has more than two decades of relevant experience, including serving as head of PIMCO’s Asia-Pacific business, co-head of PIMCO’s institutional business in the Americas, and head of PIMCO’s global advisory effort. Mr. Mogelof is a highly experienced leader and manager of people. During the course of his time at PIMCO, he held several leadership roles spanning multiple geographies, overseeing hundreds of employees.

    About KKR Income Opportunities Fund

    KIO is a diversified, closed-end management investment company managed by KKR Credit Advisors (US) LLC (“KKR Credit”), an indirect subsidiary of KKR & Co. Inc. KIO’s primary investment objective is to seek a high level of current income with a secondary objective of capital appreciation. KIO will seek to achieve its investment objective by investing primarily in first- and second-lien secured loans, unsecured loans and high yield corporate debt instruments. It expects to employ a dynamic strategy of investing in a targeted portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers and implementing hedging strategies in order to achieve attractive risk-adjusted returns. Please visit www.kkrfunds.com/kio for additional information.

    About KKR Credit

    Launched by KKR in 2004, KKR Credit invests on behalf of its managed funds, clients and accounts across the corporate credit spectrum, including secured credit, bank loans and high yield securities and alternative assets such as mezzanine financing, special situations investing and structured finance. With approximately 280 employees, including over 130 investment professionals, KKR Credit’s investment teams are closely aligned with KKR’s wealth of private equity investment and industry resources.

    About KKR

    KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, credit and real assets, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

    Forward Looking Statements

    This press release contains certain statements that may include “forward-looking statements” within the meaning of the federal securities laws. All statements, other than statements of historical fact, included herein are “forward-looking statements.” The forward-looking statements are based on the Fund’s and KKR’s beliefs, assumptions and expectations of its future performance, taking into account all information currently available to it. These beliefs, assumptions and expectations can change as a result of many possible events or factors, not all of which are known to the Fund or KKR or are within their control. The Fund and KKR do not undertake any obligation to update any forward-looking statements to reflect circumstances or events that occur after the date on which such statements were made except as required by law.

    Fund Disclaimer

    This press release is not an offer to sell securities and is not soliciting an offer to buy securities in any jurisdiction where the offer or sale is not permitted. Investors should consider the Fund’s investment objectives, risks, charges and expenses carefully before investing. The Fund’s prospectus, which contains this and other important information about the Fund, should be read carefully before investing. A copy of the Fund’s prospectus can be obtained on the Fund’s website. An investment in the Fund should not constitute a complete investment program.

    The investment return, price, distribution rate, market value and net asset value (“NAV”) of a fund’s shares will fluctuate with market conditions. Listed closed-end funds frequently trade at a discount to their NAV, which may increase an investor’s risk of loss. There is no assurance that the Fund will meet its investment objectives. The Fund’s distribution rates may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors. There can be no assurance that a change in market conditions or other factors will not result in a change in the Fund distribution rate at a future time.

    An investment in the Fund is not appropriate for all investors and is not intended to be a complete investment program. An investment in the Fund involves risks, including the risk that you may receive little or no return on your investment or that you may lose part or even all of your investment. Therefore, prospective investors should consider carefully the Fund’s investment objectives, risks, charges and expenses and should consult with a tax, legal or financial advisor before making any investment decision. The market price (in the case of KIO) and the NAV of the Fund’s shares will fluctuate, and it is possible to lose money by investing in the Fund. Past performance is not a guarantee of future results.

    The Fund will invest in loans and other types of fixed‐income instruments and securities. Such investments may be secured, partially secured or unsecured and may be unrated, and whether or not rated, may have speculative characteristics. The market price of the Fund’s investments will change in response to changes in interest rates and other factors. Generally, when interest rates rise, the values of fixed‐income instruments fall, and vice versa.

    Use of leverage creates an opportunity for increased income and return for Common Shareholders but, at the same time, creates risks, including the likelihood of greater volatility in the NAV and market price of, and distributions on, the Common Shares. In particular, leverage may magnify interest rate risk, which is the risk that the prices of portfolio securities will fall (or rise) if market interest rates for those types of securities rise (or fall). As a result, leverage may cause greater changes in the Fund’s NAV, which will be borne entirely by the Fund’s Common Shareholders.

    Get the next $KIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KIO
    $KKR

    CompanyDatePrice TargetRatingAnalyst
    KKR & Co. Inc.
    $KKR
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    KKR & Co. Inc.
    $KKR
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    1/14/2026$131.00Buy → Hold
    TD Cowen
    KKR & Co. Inc.
    $KKR
    12/11/2025$176.00Buy
    UBS
    KKR & Co. Inc.
    $KKR
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    KKR & Co. Inc.
    $KKR
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    6/30/2025$150.00Overweight
    Piper Sandler
    KKR & Co. Inc.
    $KKR
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KIO
    $KKR
    SEC Filings

    View All

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    3/2/26 8:32:24 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:01:59 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:00:39 PM ET
    $KKR
    Investment Managers
    Finance

    $KIO
    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    KKR to Present at the 2026 RBC Capital Markets Financial Institutions Conference

    KKR & Co. Inc. (NYSE:KKR) announced today that Robert H. Lewin, Chief Financial Officer, will present at the 2026 RBC Capital Markets Financial Institutions Conference on Wednesday, March 11, 2026 at 9:20AM ET. A live webcast of the presentation will be available on the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. For those unable to listen to the live webcast, a replay will be available on the website shortly after the event. Any questions regarding the webcast may be addressed to KKR's Investor Relations team at [email protected]. ABOUT KKR KKR is a leading global investment firm that offers alternative asset management as well as

    2/26/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2025 Results; Declares First Quarter 2026 Distribution of $0.48 per Share

    PHILADELPHIA and NEW YORK, Feb. 25, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter and year ended December 31, 2025, and that its board of directors has declared a first quarter 2026 distribution of $0.48 per share. Financial and Operating Highlights for the Quarter Ended December 31, 2025(1)Net investment income of $0.48 per share, compared to $0.57 per share for the quarter ended September 30, 2025Adjusted net investment income(2) of $0.52 per share, compared to $0.57 per share for the q

    2/25/26 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    $KIO
    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Group Partnership L.P. sold $807,546,115 worth of shares (19,715,000 units at $40.96), disposed of 402,773 shares and gifted 81,213 shares (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/4/26 7:46:52 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KIO
    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KIO
    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KIO
    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    Peak Re Welcomes KKR and Quadrantis Capital as Minority Investors

    Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden

    10/20/25 9:05:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Appoints Craig Arnold to Board

    KKR & Co. Inc. (NYSE:KKR) today announced that Craig Arnold has been appointed to the Board of Directors effective September 23, 2025. His appointment will bring the number of independent directors to eleven out of a total of fifteen Board seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924641078/en/Craig Arnold Mr. Arnold is the former Chairman and Chief Executive Officer of Eaton Corporation, a global intelligent power management company. KKR's other Board members are: Henry Kravis (Co-Founder and Co-Executive Chairman of KKR), George Roberts (Co-Founder and Co-Executive Chairman of KKR), Joseph Bae (Co-Executive Of

    9/24/25 4:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KIO
    $KKR
    Financials

    Live finance-specific insights

    View All

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2025 Results; Declares First Quarter 2026 Distribution of $0.48 per Share

    PHILADELPHIA and NEW YORK, Feb. 25, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter and year ended December 31, 2025, and that its board of directors has declared a first quarter 2026 distribution of $0.48 per share. Financial and Operating Highlights for the Quarter Ended December 31, 2025(1)Net investment income of $0.48 per share, compared to $0.57 per share for the quarter ended September 30, 2025Adjusted net investment income(2) of $0.52 per share, compared to $0.57 per share for the q

    2/25/26 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    Keurig Dr Pepper Announces Updated Financing Plan for JDE Peet's Acquisition

    Company strengthens balance sheet by further reducing projected leverage and attracts additional high-quality investorsBURLINGTON, Mass. and FRISCO, Texas, Feb. 23, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP, ", the Company", )) today announced updated financing plans and transaction timelines for the acquisition of JDE Peet's and subsequent planned separation into two independent companies ("Beverage Co." and "Global Coffee Co." pending the announcement of official corporate names).Key developments include:A targeted close of the JDE Peet's acquisition in early April 2026, with expected combined net leverage of approximately 4.5x1An agreement to upsize the previously announced B

    2/23/26 4:30:00 PM ET
    $APO
    $KDP
    $KKR
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples

    $KIO
    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance